Skip to main content

Posts

Showing posts with the label Critical Medicines Act 2025

Free Internship Opportunities for Pharmacy Students

  If you’re a pharmacy student looking to gain real-world experience, pharmacy internships are the best way to start. Whether you’re pursuing an internship in a hospital, pharmaceutical company, or through an online platform, these programs give you hands-on exposure to the pharmaceutical world. A pharmacy internship helps you understand the fundamentals of drug development, patient care, and regulatory compliance. It’s also a gateway to career opportunities in hospitals, pharmaceutical companies, and research organizations. ๐Ÿงช What Is a Pharmacy Internship? A pharmacy internship program is a structured learning experience where students apply theoretical knowledge in practical settings such as hospitals, community pharmacies, or pharma industries. Through these pharmacy internship programs, students learn to: Manage prescriptions and patient counseling Understand drug formulations and manufacturing Assist in quality assurance and pharmacovigilance ...

Top 10 Breakthrough Medicines Approved in 2025 - New Drug Modalities, FDA Approvals & Future of Pharmacy

  ๐Ÿš€ Introduction: A Historic Year for Drug Approvals The year 2025 stands out as one of the most transformative years in the history of pharmaceutical innovation. With several new drugs approved in 2025 , the global medical community is witnessing breakthroughs in oncology, rare diseases, genetic disorders, and pain management. The new drug modalities 2025 —including RNA interference therapies , bispecific antibodies , and non-opioid pain drugs —are redefining how we treat complex diseases. Let’s explore the most impactful FDA approvals 2025 and what they mean for the future of pharmacy . ๐Ÿ’Š Top 10 Breakthrough Medicines Approved in 2025 1. Datopotamab Deruxtecan (Datroway) Approval Date: January 17, 2025 Use: HER2-negative breast cancer Why It Matters: One of the most promising new drugs approved in 2025 , expanding targeted therapy options for resistant cancers. 2. Suzetrigine (Journavx) Approval Date: January 30, 2025 ...